Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03744676 · ClinicalTrials.gov registry record · Phase 2
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
A Phase 2 study, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
NCT03744676 is a Phase 2 study that has completed, run by Juno Therapeutics, a Subsidiary of Celgene. The registered enrollment target is 104 participants.
The verdict
NCT03744676, a Phase 2 study, has completed, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, Phase 2 study to determine the safety, PK, and efficacy of lisocabtagene maraleucel (JCAR017) in subjects who have relapsed from, or are refractory to, two lines of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) in the outpatient setting. Subjects will receive treatment with JCAR017 and will be followed for up to 2 years.
Interventions
- BIOLOGICAL lisocabtagene maraleucel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2018-11-29 |
| Est. Completion | 2023-09-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03744676
The ClinicalTrials.gov registry entry for NCT03744676 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Juno Therapeutics, a Subsidiary of Celgene, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lisocabtagene maraleucel is the first listed.
NCT03744676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03744676 about?
NCT03744676 is a clinical study titled "A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)". This is an open-label, multicenter, Phase 2 study to determine the safety, PK, and efficacy of lisocabtagene maraleucel (JCAR017) in subjects who have relapsed from, or are refractory to, two lines of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) in the outpatient setting. Subj...
What is the current status of trial NCT03744676?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2018-11-29. Estimated completion is 2023-09-22.
What interventions are being tested in trial NCT03744676?
The interventions under investigation include: lisocabtagene maraleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT03744676?
This trial is sponsored by Juno Therapeutics, a Subsidiary of Celgene, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.